Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without preval...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopaschuk, Gary D., Verma, Subodh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
STATE-OF-THE-ART REVIEW
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315190/
https://www.ncbi.nlm.nih.gov/pubmed/32613148
http://dx.doi.org/10.1016/j.jacbts.2020.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315190/
https://www.ncbi.nlm.nih.gov/pubmed/32613148
http://dx.doi.org/10.1016/j.jacbts.2020.02.004

Ejemplares similares